The thesis I am interested in is whether IFN is likely to have a place in the HCV universe after anti-virals become SoC. I have previous supposed that there was a good chance of a very high relapse rate if an immune modulator does not follow direct anti-virals. With this data I would now state that thesis with more confidence - making it a predict.
I respectfully disagree.
When a treatment regimen includes only one direct-antiviral agent, as in VRTX’s PROVE-3 study, the role of interferon and ribavirin in mopping up mutations to the single antiviral is obvious and unquestioned.
However, when a cocktail includes multiple* antiviral drugs with complimentary resistance profiles, the need for interferon or another immunomodulator is far from clear.
*The optimal number will likely be three, as in HIV therapy.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.